Acorn Bioventures, L.P. - May 15, 2025 Form 4 Insider Report for OnKure Therapeutics, Inc. (OKUR)

Role
10%+ Owner
Signature
ACORN BIOVENTURES, L.P., By: Acorn Capital Advisors GP, LLC, its general partner, By: /s/ Anders Hove, Manager
Stock symbol
OKUR
Transactions as of
May 15, 2025
Transactions value $
$2,590,000
Form type
4
Date filed
5/19/2025, 04:43 PM
Previous filing
Oct 9, 2024

Reporting Owners (3)

Name Relationship Address Signature Signature date CIK
ACORN BIOVENTURES, L.P. 10%+ Owner 420 LEXINGTON AVE., SUITE 2626, NEW YORK ACORN BIOVENTURES, L.P., By: Acorn Capital Advisors GP, LLC, its general partner, By: /s/ Anders Hove, Manager 2025-05-19 0001766853
ACORN CAPITAL ADVISORS GP, LLC 10%+ Owner 420 LEXINGTON AVE., SUITE 2626, NEW YORK ACORN CAPITAL ADVISORS GP, LLC, By: /s/ Anders Hove, Manager 2025-05-19 0001813692
Hove Anders D 10%+ Owner 420 LEXINGTON AVE., SUITE 2626, NEW YORK /s/ Anders Hove 2025-05-19 0001365618

Transactions Table

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares held directly by Acorn Bioventures, L.P. ("Acorn"). Acorn Capital Advisors GP, LLC ("Acorn GP") is the general partner of Acorn. Anders Hove is the manager of Acorn GP. Each of Acorn GP and Mr. Hove disclaims beneficial ownership of disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
F2 Shares held directly by Acorn Bioventures 2, L.P. ("Acorn 2"). Acorn Capital Advisors GP 2, LLC ("Acorn GP 2") is the general partner of Acorn 2. Anders Hove is the manager of Acorn GP 2. Each of Acorn GP 2 and Mr. Hove disclaims beneficial ownership of disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.